FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment – CNBC

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment CNBC
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy MarketWatch
Controlled drug Ketamine a lifeline for patients with severe depression in S’pore The Straits Times
Safety and Feasibility of Intranasal Ketamine in Depression Treatment Physician’s Weekly
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PR Newswire